Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (101-110 of 190) with videos related to

Pageof 19
Sort By:
Biometrics|January 24, 2018
A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroupsThomas A Murray, Ying Yuan, Peter F Thall, et al.
The Annals of Applied Statistics|November 4, 2022
BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALSRuitao Lin, Haolun Shi, Guosheng Yin, et al.
Clinical Trials (London, England)|September 3, 2014
Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-findingPeter F Thall, Richard C Herrick, Hoang Q Nguyen, et al.
Blood|July 5, 2003
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AMLElihu H Estey, Peter F Thall, Xuemei Wang, et al.
Statistics in Medicine|April 12, 2007
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoringPeter F Thall, Leiko H Wooten, Christopher J Logothetis, et al.
Biometrics|March 16, 2011
Optimizing the concentration and bolus of a drug delivered by continuous infusionPeter F Thall, Aniko Szabo, Hoang Q Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2023
Novel Clinical Trial Designs with Dose Optimization to Improve Long-term OutcomesPeter F Thall, Yong Zang, Andrew G Chapple, et al.
Current Opinion in Oncology|June 30, 2009
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemiaBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Journal of the National Cancer Institute|November 1, 2007
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimensPeter F Thall, Christopher Logothetis, Lance C Pagliaro, et al.
Statistics in Medicine|February 15, 2003
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesPeter F Thall, J Kyle Wathen, B Nebiyou Bekele, et al.
Pageof 19

Showing results (101-110 of 190) with videos related to

Sort By:
Pageof 19
Biometrics|January 24, 2018
A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroupsThomas A Murray, Ying Yuan, Peter F Thall, et al.
The Annals of Applied Statistics|November 4, 2022
BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALSRuitao Lin, Haolun Shi, Guosheng Yin, et al.
Clinical Trials (London, England)|September 3, 2014
Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-findingPeter F Thall, Richard C Herrick, Hoang Q Nguyen, et al.
Blood|July 5, 2003
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AMLElihu H Estey, Peter F Thall, Xuemei Wang, et al.
Statistics in Medicine|April 12, 2007
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoringPeter F Thall, Leiko H Wooten, Christopher J Logothetis, et al.
Biometrics|March 16, 2011
Optimizing the concentration and bolus of a drug delivered by continuous infusionPeter F Thall, Aniko Szabo, Hoang Q Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2023
Novel Clinical Trial Designs with Dose Optimization to Improve Long-term OutcomesPeter F Thall, Yong Zang, Andrew G Chapple, et al.
Current Opinion in Oncology|June 30, 2009
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemiaBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Journal of the National Cancer Institute|November 1, 2007
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimensPeter F Thall, Christopher Logothetis, Lance C Pagliaro, et al.
Statistics in Medicine|February 15, 2003
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesPeter F Thall, J Kyle Wathen, B Nebiyou Bekele, et al.
Pageof 19